{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:24:59Z","timestamp":1768278299362,"version":"3.49.0"},"reference-count":104,"publisher":"Mattioli1885","issue":"1","license":[{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Multidiscip Respir Med"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40248-019-0195-2","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:02:52Z","timestamp":1572825772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Immunostimulants in respiratory diseases: focus on Pidotimod"],"prefix":"10.5826","volume":"14","author":[{"given":"Francesca","family":"Puggioni","sequence":"first","affiliation":[]},{"given":"Magna","family":"Alves-Correia","sequence":"additional","affiliation":[]},{"given":"Manar-Farouk","family":"Mohamed","sequence":"additional","affiliation":[]},{"given":"Niccol\u00f2","family":"Stomeo","sequence":"additional","affiliation":[]},{"given":"Riccardo","family":"Mager","sequence":"additional","affiliation":[]},{"given":"Massimiliano","family":"Marinoni","sequence":"additional","affiliation":[]},{"given":"Francesca","family":"Racca","sequence":"additional","affiliation":[]},{"given":"Giovanni","family":"Paoletti","sequence":"additional","affiliation":[]},{"given":"Gilda","family":"Varricchi","sequence":"additional","affiliation":[]},{"given":"Veronica","family":"Giorgis","sequence":"additional","affiliation":[]},{"given":"Giovanni","family":"Melioli","sequence":"additional","affiliation":[]},{"given":"Giorgio Walter","family":"Canonica","sequence":"additional","affiliation":[]},{"given":"Enrico","family":"Heffler","sequence":"additional","affiliation":[]}],"member":"27750","published-online":{"date-parts":[[2019,11,4]]},"reference":[{"key":"195_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12948-015-0012-1","volume":"13","author":"BE Ferrario","year":"2015","unstructured":"Ferrario BE, Garuti S, Braido F, Canonica GW. Pidotimod: the state of art. Clin Mol Allergy. 2015;13:8.","journal-title":"Clin Mol Allergy"},{"key":"195_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/039463200501800207","volume":"18","author":"G Lanzilli","year":"2005","unstructured":"Lanzilli G, Falchetti R, Tricarico M, Ungheri D, Fuggetta MP. In vitro effects of an immunostimulating bacterial lysate on human lymphocyte function. Int J Immunopathol Pharmacol. 2005;18:245\u201354.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"195_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.imlet.2011.03.006","volume":"138","author":"B Morandi","year":"2011","unstructured":"Morandi B, Agazzi A, D'Agostino A, Antonini F, Costa G, Sabatini F, et al. A mixture of bacterial mechanical lysates is more efficient than single strain lysate and of bacterial-derived soluble products for the induction of an activating phenotype in human dendritic cells. Immunol Lett. 2011;138:86\u201391.","journal-title":"Immunol Lett"},{"key":"195_CR4","first-page":"209","volume":"10","author":"M Huber","year":"2005","unstructured":"Huber M, Mossmann H, Bessler WG. Th1-orientated immunological properties of the bacterial extract OM-85-BV. Eur J Med Res. 2005;10:209\u201317.","journal-title":"Eur J Med Res"},{"key":"195_CR5","first-page":"CD004974","volume":"4","author":"BE Del-Rio-Navarro","year":"2006","unstructured":"Del-Rio-Navarro BE, Espinosa Rosales F, Flenady V, Sienra-Monge JJ. Immunostimulants for preventing respiratory tract infection in children. Cochrane Database Syst Rev. 2006;4:CD004974.","journal-title":"Cochrane Database Syst Rev"},{"key":"195_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12519-010-0001-x","volume":"6","author":"UB Schaad","year":"2010","unstructured":"Schaad UB. OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review. World J Pediatr. 2010;6:5\u201312.","journal-title":"World J Pediatr"},{"key":"195_CR7","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1378\/chest.119.6.1742","volume":"119","author":"MD Guti\u00e9rrez-Tarango","year":"2001","unstructured":"Guti\u00e9rrez-Tarango MD, Berber A. Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract infections in children during 12 months. Chest. 2001;119:1742\u20138.","journal-title":"Chest"},{"key":"195_CR8","first-page":"17","volume":"26","author":"D G\u00f3mez Barreto","year":"1998","unstructured":"G\u00f3mez Barreto D, De la Torre C, Alvarez A, Faure A, Berber A. Safety and efficacy of OM-85-BV plus amoxicillin\/clavulanate in the treatment of subacutesinusitis and the prevention of recurrent infections in children. Allergol Immunopathol (Madr). 1998;26:17\u201322.","journal-title":"Allergol Immunopathol (Madr)"},{"key":"195_CR9","first-page":"276","volume":"55","author":"A Macchi","year":"2005","unstructured":"Macchi A, Vecchia LD. Open comparative, randomized controlled clinical study of a new immunostimulating bacterial lysate in the prophylaxis of upper respiratory tract infections. Arzneimittelforschung. 2005;55:276\u201381.","journal-title":"Arzneimittelforschung"},{"key":"195_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.pupt.2015.03.006","volume":"33","author":"F Braido","year":"2015","unstructured":"Braido F, Melioli G, Cazzola M, Fabbri L, Blasi F, Moretta L, et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced immunological approach in COPD exacerbation). Pulm Pharmacol Ther. 2015;33:75\u201380.","journal-title":"Pulm Pharmacol Ther"},{"key":"195_CR11","doi-asserted-by":"publisher","first-page":"6868","DOI":"10.4049\/jimmunol.180.10.6868","volume":"180","author":"G Rosa De la","year":"2008","unstructured":"De la Rosa G, Yang D, Tewary P, Varadhachary A, Oppenheim JJ. Lactoferrin acts as an Alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses. J Immunol. 2008;180:6868\u201376.","journal-title":"J Immunol"},{"key":"195_CR12","doi-asserted-by":"publisher","first-page":"e22504","DOI":"10.1371\/journal.pone.0022504","volume":"6","author":"P Puddu","year":"2011","unstructured":"Puddu P, Latorre D, Carollo M, Catizone A, Ricci G, Valenti P, et al. Bovine Lactoferrin counteracts toll-like receptor mediated activation signals in antigen presenting cells. PLoS One. 2011;6:e22504.","journal-title":"PLoS One"},{"key":"195_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/icb.2009.86","volume":"88","author":"I Bournazou","year":"2010","unstructured":"Bournazou I, Mackenzie KJ, Duffin R, Rossi AG, Gregory CD. Inhibition of eosinophil migration by lactoferrin. Immunol Cell Biol. 2010;88:220\u20133.","journal-title":"Immunol Cell Biol"},{"issue":"65","key":"195_CR14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0006-2952(02)01651-9","volume":"15","author":"S He","year":"2003","unstructured":"He S, McEuen AR, Blewett SA, Li P, Buckley MG, Leufkens P, et al. The inhibition of mast cell activation by neutrophil lactoferrin: uptake by mast cells and interaction with tryptase, chymase and cathepsin G. Biochem Pharmacol. 2003;15(65):1007\u201315.","journal-title":"Biochem Pharmacol"},{"key":"195_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1139\/o06-058","volume":"84","author":"R Fischer","year":"2006","unstructured":"Fischer R, Debbabi H, Dubarry M, Boyaka P, Tom\u00e9 D. Regulation of physiological and pathological Th1 and Th2 responses by lactoferrin. Biochem Cell Biol. 2006;84:303\u201311.","journal-title":"Biochem Cell Biol"},{"key":"195_CR16","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1001\/jama.2009.1403","volume":"302","author":"P Manzoni","year":"2009","unstructured":"Manzoni P, Rinaldi M, Cattani S, Pugni L, Romeo MG, Messner H, et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA. 2009;302:1421\u20138.","journal-title":"JAMA"},{"key":"195_CR17","first-page":"7","volume":"16","author":"B Euba","year":"2017","unstructured":"Euba B, L\u00f3pez-L\u00f3pez N, Rodr\u00edguez-Arce I, Fern\u00e1ndez-Calvet A, Barber\u00e1n M, Caturla N, et al. Resveratrol therapeutics combines both antimicrobial and immunomodulatory properties against respiratory infection by nontypeable Haemophilus influenza. Sci Rep. 2017;16:7\u201312860.","journal-title":"Sci Rep"},{"key":"195_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1080\/01616412.2015.1133027","volume":"38","author":"Q Su","year":"2016","unstructured":"Su Q, Pu H, Hu C. Neuroprotection by combination of resveratrol and enriched environment against ischemic brain injury in rats. Neurol Res. 2016;38:60\u20138.","journal-title":"Neurol Res"},{"key":"195_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s10753-011-9310-z","volume":"35","author":"G Lanzilli","year":"2012","unstructured":"Lanzilli G, Cottarelli A, Nicotera G, Guida S, Ravagnan G, Fuggetta MP. Anti- inflammatory effect of resveratrol and polydatin by in vitro IL-17 modulation. Inflammation. 2012;35:240\u20138.","journal-title":"Inflammation"},{"key":"195_CR20","doi-asserted-by":"publisher","first-page":"e49761","DOI":"10.1371\/journal.pone.0049761","volume":"7","author":"M Gertz","year":"2012","unstructured":"Gertz M, Nguyen GT, Fischer F, Suenkel B, Schlicker C, Fr\u00e4nzel B, et al. A molecular mechanism for direct Sirtuin activation by resveratrol. PLoS One. 2012;7:e49761.","journal-title":"PLoS One"},{"key":"195_CR21","doi-asserted-by":"publisher","first-page":"6572","DOI":"10.3748\/wjg.v21.i21.6572","volume":"21","author":"J Yao","year":"2015","unstructured":"Yao J, Wei C, Wang JY, Zhang R, Li YX, Wang LS. Effect of resveratrol on Treg\/Th17 signaling and ulcerative colitis treatment in mice. World J Gastroenterol. 2015;21:6572\u201381.","journal-title":"World J Gastroenterol"},{"key":"195_CR22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/bcpt.12129","volume":"114","author":"J Knobloch","year":"2014","unstructured":"Knobloch J, Wahl C, Feldmann M, Jungck D, Strauch J, Stoelben E, et al. Resveratrol attenuates the release of inflammatory cytokines from human bronchial smooth muscle cells exposed to Lipoteichoic acid in chronic obstructive pulmonary disease. Basic Clin Pharmacol Toxicol. 2014;114:202\u20139.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"195_CR23","doi-asserted-by":"publisher","first-page":"34445","DOI":"10.1038\/srep34445","volume":"6","author":"CS Andrews","year":"2016","unstructured":"Andrews CS, Matsuyama S, Lee BC, Li JD. Resveratrol suppresses NTHi- induced inflammation via up-regulation of the negative regulator MyD88 short. Sci Rep. 2016;6:34445.","journal-title":"Sci Rep"},{"key":"195_CR24","first-page":"6099","volume":"14","author":"S Wu","year":"2017","unstructured":"Wu S, Huang J. Resveratrol alleviates Staphylococcus aureus pneumonia by inhibition of the NLRP3. Exp Ther Med. 2017;14:6099\u2013104.","journal-title":"Exp Ther Med"},{"key":"195_CR25","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/intimm\/12.6.807","volume":"12","author":"G Becker De","year":"2000","unstructured":"De Becker G, Moulin V, Pajak B, Bruck C, Francotte M, Thiriart C, et al. The adjuvant monophosphoryl lipid a increases the function of antigen-presenting cells. Int Immunol. 2000;12:807\u201315.","journal-title":"Int Immunol"},{"key":"195_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/infdis\/174.2.361","volume":"174","author":"DG Heppner","year":"1996","unstructured":"Heppner DG, Gordon DM, Gross M, Wellde B, Leitner W, Krzych U, et al. Safety, immunogenicity, and efficacy of plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J Infect Dis. 1996;174:361\u20136.","journal-title":"J Infect Dis"},{"key":"195_CR27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S0264-410X(97)00254-5","volume":"16","author":"S Thoelen","year":"1998","unstructured":"Thoelen S, Van Damme P, Mathei C, Leroux-Roels G, Desombere I, Safary A, et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine. 1998;16:708\u201314.","journal-title":"Vaccine"},{"key":"195_CR28","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/IGC.0b013e3181a23c0e","volume":"19","author":"R Konno","year":"2009","unstructured":"Konno R, Dobbelaere KO, Godeaux OO, Tamura S, Yoshikawa H. Immunogenicity, reactogenicity, and safety of human papillomavirus 16\/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7. Int J Gynecol Cancer. 2009;19:905\u201311.","journal-title":"Int J Gynecol Cancer"},{"key":"195_CR29","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/j.1398-9995.2005.00762.x","volume":"60","author":"F Puggioni","year":"2005","unstructured":"Puggioni F, Durham SR, Francis JN. Monophosphoryl lipid a (MPL) promotes allergen-induced immune deviation in favour of Th1responses. Allergy. 2005;60:678\u201384.","journal-title":"Allergy"},{"key":"195_CR30","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2249.2010.04106.x","volume":"160","author":"M Rosewich","year":"2010","unstructured":"Rosewich M, Schulze J, Eickmeier O, Telles T, Rose MA, Schubert R, et al. Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid a in children. Clin Exp Immunol. 2010;160:403\u201310.","journal-title":"Clin Exp Immunol"},{"key":"195_CR31","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1128\/IAI.00022-11","volume":"79","author":"CD Romero","year":"2011","unstructured":"Romero CD, Varma TK, Hobbs JB, Reyes A, Driver B, Sherwood ER. The toll-like receptor 4 agonist Monophosphoryl lipid a augments innate host resistance to systemic bacterial infection. Infect Immun. 2011;79:3576\u201387.","journal-title":"Infect Immun"},{"key":"195_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00024382-199410000-00007","volume":"2","author":"ME Astiz","year":"1994","unstructured":"Astiz ME, Galera A, Saha DC, Carpati C, Rackow EC. Monophosphoryl lipid a protects against gram-positive sepsis and tumor necrosis factor. Shock. 1994;2:271\u20134.","journal-title":"Shock"},{"key":"195_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1824-7288-39-75","volume":"39","author":"GV Zuccotti","year":"2013","unstructured":"Zuccotti GV, Mameli C. Pidotimod: the past and present. Ital J Pediatr. 2013;39:75.","journal-title":"Ital J Pediatr"},{"key":"195_CR34","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.intimp.2009.08.010","volume":"9","author":"C Giagulli","year":"2009","unstructured":"Giagulli C, Noerder M, Avolio M, Becker PD, Fiorentini S, Guzman CA, et al. Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level. Int Immunopharmacol. 2009;9:1366\u201373.","journal-title":"Int Immunopharmacol"},{"key":"195_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.pupt.2017.03.005","volume":"44","author":"D Trabattoni","year":"2017","unstructured":"Trabattoni D, Clerici M, Centanni S, Mantero M, Garziano M, Blasi F. Immunomodulatory effects of pidotimod in adults with communityacquired pneumonia undergoing standard antibiotic therapy. Pulm Pharmacol Ther. 2017;44:24\u20139.","journal-title":"Pulm Pharmacol Ther"},{"key":"195_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/039463200902200201","volume":"22","author":"P Riboldi","year":"2009","unstructured":"Riboldi P, Gerosa M, Meroni PL. Pidotimod: a reappraisal. Int J Immunopathol Pharmacol. 2009;22:255\u201362.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"195_CR37","first-page":"25","volume":"52","author":"GC Torre De la","year":"2005","unstructured":"De la Torre GC, Pacheco R\u00edos A, Escalante Dom\u00ednguez AJ, del R\u00edo Navarro BE. Comparative meta-analysis of immunoestimulant agents used in pediatric patients in Mexico. Rev Alerg Mex. 2005;52:25\u201338.","journal-title":"Rev Alerg Mex"},{"key":"195_CR38","first-page":"174","volume":"9","author":"P Careddu","year":"1992","unstructured":"Careddu P, Alfano S, Zavattini G. Pidotimod III the prophylaxis of recurrent acute tonsillitis III childhood. Adv Ther. 1992;9:174\u201383.","journal-title":"Adv Ther"},{"key":"195_CR39","first-page":"15","volume":"XIX","author":"P Marelli","year":"1993","unstructured":"Marelli P, LupettiA SS, Uslenghi C, Girardello R, Campa M. Potenziamento della resistenza aile infezioni virali e batteriche dopo somministrazione di pidotimod nel topo. Drugs Exp Clin Res. 1993;XIX:15\u201321.","journal-title":"Drugs Exp Clin Res"},{"key":"195_CR40","doi-asserted-by":"publisher","first-page":"101818","DOI":"10.1016\/j.pupt.2019.101818","volume":"58","author":"Francesca Santamaria","year":"2019","unstructured":"Santamaria F, Montella S, Stocchero M, Pirillo P, Bozzetto S, Giordano G, Poeta M, Baraldi E. Effects of pidotimod and bifidobacteria mixture on clinical symptoms and urinary metabolomic profile of children with recurrent respiratory infections: A randomized placebo-controlled trial. Pulm Pharmacol Ther. 2019;58:101818.","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"key":"195_CR41","first-page":"S152","volume":"26","author":"L Cantarini","year":"2008","unstructured":"Cantarini L, Brogna A, Fioravanti A, Galeazzi M. Henoch-Sch\u00f6nlein purpura associated with pidotimod therapy. Clin Exp Rheumatol. 2008;26:S152.","journal-title":"Clin Exp Rheumatol"},{"issue":"12A","key":"195_CR42","first-page":"1525","volume":"44","author":"GR Burgio","year":"1994","unstructured":"Burgio GR, Marseglia GL, Severi F, De Benedetti F, Masarone M, Ottolenghi A, et al. Immunoactivation by pidotimod in children with recurrent respiratory infections. Arzneimittelforschung. 1994;44(12A):1525\u20139.","journal-title":"Arzneimittelforschung"},{"issue":"12A","key":"195_CR43","first-page":"1506","volume":"44","author":"P Careddu","year":"1994","unstructured":"Careddu P. Role of immunoactivation with pidotimod in recurrent respiratory infections in childhood. Arzneimittelforschung. 1994;44(12A):1506\u201311.","journal-title":"Arzneimittelforschung"},{"key":"195_CR44","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/90609","volume":"2","author":"S Akira","year":"2001","unstructured":"Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675\u201380.","journal-title":"Nat Immunol"},{"key":"195_CR45","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nri1391","volume":"4","author":"S Akira","year":"2004","unstructured":"Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499\u2013511.","journal-title":"Nat Rev Immunol"},{"key":"195_CR46","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.1038\/sj.onc.1209954","volume":"25","author":"TD Gilmore","year":"2006","unstructured":"Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006;25:6680\u20134.","journal-title":"Oncogene"},{"key":"195_CR47","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1385\/CT:6:2:111","volume":"6","author":"AR Brasier","year":"2006","unstructured":"Brasier AR. The NF-kappaB regulatory network. Cardiovasc Toxicol. 2006;6:111\u201330.","journal-title":"Cardiovasc Toxicol"},{"key":"195_CR48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1824-7288-39-29","volume":"39","author":"S Carta","year":"2013","unstructured":"Carta S, Silvestri M, Rossi GA. Modulation of airway epithelial cell functions by Pidotimod: NF-kB cytoplasmatic expression and its nuclear translocation are associated with an increased TLR-2 expression. Ital J Pediatr. 2013;39:29.","journal-title":"Ital J Pediatr"},{"key":"195_CR49","first-page":"71","volume":"11","author":"A Pugliese","year":"1995","unstructured":"Pugliese A, Uslenghi C, Torre D, D\u2019Alonzo L, Corgnati F, Girardello R. Evaluation of the effect of pidotimod on the in vitro production of interferons. Int J Immunother. 1995;11:71\u20136.","journal-title":"Int J Immunother"},{"key":"195_CR50","first-page":"64","volume":"33","author":"Y Zhou","year":"2012","unstructured":"Zhou Y, Dai Y. Comparison of effects of Pidotimod and spleen aminopeptide on clinical symptoms and Th1\/Th2 cytokines in children with RRI. Chin J Bioch Pharm. 2012;33:64\u20139.","journal-title":"Chin J Bioch Pharm"},{"key":"195_CR51","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1081\/JAS-120026085","volume":"41","author":"D Gourgiotis","year":"2004","unstructured":"Gourgiotis D, Papadopoulos NG, Bossios A, Zamanis P, Saxoni-Papageorgiou P. Immune modulator pidotimod decreases the in vitro expression of CD30 in peripheral blood mononuclear cells of atopic asthmatic and normal children. J Asthma. 2004;41:285\u20137.","journal-title":"J Asthma"},{"key":"195_CR52","first-page":"253","volume":"27","author":"GV Zuccotti","year":"2013","unstructured":"Zuccotti GV, Mameli C, Trabattoni D, Beretta S, Biasin M, Guazzarotti L, et al. Immunomodulating activity of Pidotimod in children with Down syndrome. J Biol Regul Homeost Agents. 2013;27:253\u20138.","journal-title":"J Biol Regul Homeost Agents"},{"key":"195_CR53","first-page":"34","volume":"10","author":"EE Lokshina","year":"2011","unstructured":"Lokshina EE, Kravchenko OV, Zaytseva OV. Pidotimod in treatment of children with acute respiratory infection with concomitant recurrent obstructive syndrome. Curr Paediatr. 2011;10:34\u201341.","journal-title":"Curr Paediatr"},{"key":"195_CR54","unstructured":"Macchi A, Terranova P, Digilio E, Simoncini D, Peirolo A, Castelnuovo G. Nasal cell vitality: the Pidotimod activity in children\u2019s recurrent respiratory infections. Rhinologist. 2017;3:15\u201323."},{"key":"195_CR55","unstructured":"Mailland F, Coppi G, Silingardi S. Pharmacokinetics and oral bioavailability of pidotimod in humans. Arzneimittelforschung. 1994;44(12A):1465\u20139."},{"key":"195_CR56","first-page":"1454","volume":"44 II","author":"K Adams","year":"1994","unstructured":"Adams K, Allen JA, Brooker PC, Henderson L, Jones E, Proudlock RJ, et al. Genotoxicity testing of Pidotimod in vivo and in vitro. Arzneim Forsch Drug Res. 1994;44 II:1454\u20139.","journal-title":"Arzneim Forsch Drug Res"},{"key":"195_CR57","first-page":"30310","volume":"18","author":"GBD 2016 LRI Collaborators","year":"2018","unstructured":"GBD 2016 LRI Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet Infect Dis. 2018;18:30310\u20134.","journal-title":"Lancet Infect Dis"},{"key":"195_CR58","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095\u2013128.","journal-title":"Lancet"},{"key":"195_CR59","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(03)12162-9","volume":"361","author":"T Heikkinen","year":"2003","unstructured":"Heikkinen T, J\u00e4rvinen A. The common cold. Lancet. 2003;361:51\u20139.","journal-title":"Lancet."},{"key":"195_CR60","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1152\/ajplung.00365.2011","volume":"302","author":"S Othumpangat","year":"2012","unstructured":"Othumpangat S, Regier M, Piedimonte G. Nerve growth factor modulates human rhinovirus infection in airway epithelial cells by controlling ICAM-1 expression. Am J Physiol Lung Cell Mol Physiol. 2012;302:1057\u201366.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"195_CR61","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/nm1477","volume":"12","author":"MD Jong De","year":"2006","unstructured":"De Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, et al. Fatal outcome of human influenza a (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12:1203\u20137.","journal-title":"Nat Med"},{"key":"195_CR62","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nature05495","volume":"445","author":"D Kobasa","year":"2007","unstructured":"Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, Ebihara H, et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature. 2007;445:319\u201323.","journal-title":"Nature"},{"key":"195_CR63","volume-title":"Medical Microbiology","author":"PV Dasaraju","year":"1996","unstructured":"Dasaraju PV, Liu C. Chapter 93: infections of the respiratory system. In: Baron S, editor. Medical Microbiology. 4th ed. Galveston: University of Texas Medical Branch at Galveston; 1996.","edition":"4"},{"key":"195_CR64","first-page":"327","volume":"385","author":"AM Smith","year":"2014","unstructured":"Smith AM, McCullers JA. Secondary bacterial infections in influenza virus infection pathogenesis. Curr Top Microbiol Immunol. 2014;385:327\u201356.","journal-title":"Curr Top Microbiol Immunol"},{"key":"195_CR65","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1365-2567.2009.03123.x","volume":"128","author":"NJ Topham","year":"2009","unstructured":"Topham NJ, Hewitt EW. Natural killer cell cytotoxicity: how do they pull the trigger? Immunology. 2009;128:7\u201315.","journal-title":"Immunology"},{"key":"195_CR66","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.freeradbiomed.2013.10.014","volume":"67","author":"JC Kash","year":"2013","unstructured":"Kash JC, Xiao Y, Davis AS, Walters KA, Chertow DS, Easterbrook JD, et al. Treatment with the reactive oxygen species scavenger EUK-207 reduces lung damage and increases survival during 1918 influenza virus infection in mice. Free Radic Biol Med. 2013;67:235\u201347.","journal-title":"Free Radic Biol Med"},{"key":"195_CR67","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.ajpath.2014.08.030","volume":"185","author":"JC Kash","year":"2015","unstructured":"Kash JC, Taubenberger JK. The role of viral, host, and secondary bacterial factors in influenza pathogenesis. Am J Pathol. 2015;185:1528\u201336.","journal-title":"Am J Pathol"},{"key":"195_CR68","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/00006454-200205000-00033","volume":"21","author":"RC Welliver","year":"2002","unstructured":"Welliver RC, Garofalo RP, Ogra PL. Beta-chemokines, but neither T helper type 1 nor T helper type 2 cytokines, correlate with severity of illness during respiratory syncytial virus infection. Pediatr Infect Dis J. 2002;21:457\u201361.","journal-title":"Pediatr Infect Dis J"},{"key":"195_CR69","first-page":"753","volume":"28","author":"M Fogli","year":"2014","unstructured":"Fogli M, Caccuri F, Iaria ML, Giagulli C, Corbellini S, Campilongo F, et al. The immunomodulatory molecule pidotimod induces the expression of the NOD-like receptor NLRP12 and attenuates TLR-induced inflammation. J Biol Regul Homeost Agents. 2014;28:753\u201366.","journal-title":"J Biol Regul Homeost Agents"},{"key":"195_CR70","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s12967-015-0649-z","volume":"13","author":"S Esposito","year":"2015","unstructured":"Esposito S, Garziano M, Rainone V, Trabattoni D, Biasin M, Senatore L, et al. Immunomodulatory activity of pidotimod administered with standard antibiotic therapy in children hospitalized for community-acquired pneumonia. J Transl Med. 2015;13:288.","journal-title":"J Transl Med"},{"key":"195_CR71","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.pupt.2017.03.005","volume":"44","author":"D Trabattoni","year":"2017","unstructured":"Trabattoni D, Clerici M, Centanni S, Mantero M, Garziano M, Blasi F. Immunomodulatory effects of pidotimod in adults with community-acquired pneumonia undergoing standard antibiotic therapy. Pulm Pharmacol Ther. 2017;44:24\u20139.","journal-title":"Pulm Pharmacol Ther"},{"key":"195_CR72","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.intimp.2018.11.043","volume":"67","author":"H Niu","year":"2019","unstructured":"Niu H, Wang R, Jia YT, Cai Y. Pidotimod, an immunostimulant in pediatric recurrent respiratory tract infections: a meta-analysis of randomized controlled trials. Int Immunopharmacol. 2019;67:35\u201345.","journal-title":"Int Immunopharmacol"},{"key":"195_CR73","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.1513\/AnnalsATS.201507-427AW","volume":"12","author":"J Wedzicha","year":"2015","unstructured":"Wedzicha J. Mechanisms of chronic obstructive pulmonary disease exacerbations. Ann Am Thorac Soc. 2015;12:S157\u20139.","journal-title":"Ann Am Thorac Soc"},{"key":"195_CR74","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) - \n                    https:\/\/goldcopd.org\n                    \n                  . Accessed the 16 July 2019."},{"issue":"10","key":"195_CR75","first-page":"1","volume":"59","author":"A Mini\u00f1o","year":"2018","unstructured":"Mini\u00f1o A, Murphy S, Xu J, Kochanek K. Deaths: final data for 2008. Natl Vital Stat Rep. 2018;59(10):1\u2013126 Available at: \n                    https:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr59\/nvsr59_10.pdf\n                    \n                  . Accessed 17 Nov 2018.","journal-title":"Natl Vital Stat Rep"},{"key":"195_CR76","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(07)61377-4","volume":"370","author":"A Buist","year":"2007","unstructured":"Buist A, McBurnie M, Vollmer W, Gillespie S, Burney P, Mannino D, et al. International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study. Lancet. 2007;370:741\u201350.","journal-title":"Lancet"},{"key":"195_CR77","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1164\/ajrccm.157.5.9709032","volume":"157","author":"TA Seemungal","year":"1998","unstructured":"Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients withchronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418\u201322.","journal-title":"Am J Respir Crit Care Med"},{"key":"195_CR78","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(07)61382-8","volume":"370","author":"JA Wedzicha","year":"2007","unstructured":"Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370:786\u201396.","journal-title":"Lancet"},{"key":"195_CR79","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1183\/09031936.00223113","volume":"44","author":"SN George","year":"2014","unstructured":"George SN, Garcha DS, Mackay AJ, Patel AR, Singh R, Sapsford RJ, et al. Human rhinovirus infection during naturally occurring COPD exacerbations. Eur Respir J. 2014;44:87\u201396.","journal-title":"Eur Respir J"},{"key":"195_CR80","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1136\/thoraxjnl-2011-200768","volume":"67","author":"SD Aaron","year":"2012","unstructured":"Aaron SD, Donaldson GC, Whitmore GA, Hurst JR, Ramsay T, Wedzicha JA. Time course and pattern of COPD exacerbation onset. Thorax. 2012;67:238\u201343.","journal-title":"Thorax"},{"key":"195_CR81","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1164\/rccm.200506-859OC","volume":"173","author":"A Papi","year":"2006","unstructured":"Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severeexacerbations. Am J Respir Crit Care Med. 2006;173:1114\u201321.","journal-title":"Am J Respir Crit Care Med"},{"key":"195_CR82","first-page":"1499","volume":"44 II","author":"G Bisetti","year":"1994","unstructured":"Bisetti G, Ciappi G, Bariffi F, Catena E, Rocco V, Vaccaro L, et al. Evaluation of the efficacy of Pidotimod on the exacerbations in patients affected with chronic bronchitis. Arzneim Forsch Drug Res. 1994;44 II:1499\u2013502.","journal-title":"Arzneim Forsch Drug Res"},{"key":"195_CR83","first-page":"1516","volume":"44","author":"A Ciaccia","year":"1994","unstructured":"Ciaccia A, et al. Pidotimod activity against chronic bronchitis exacerbations. Arzneim Forsch Drug Res. 1994;44:1516\u201320.","journal-title":"Arzneim Forsch Drug Res"},{"key":"195_CR84","first-page":"1503","volume":"44","author":"GP Benetti","year":"1994","unstructured":"Benetti GP, Illeni MT, Passera A, Bombelli G, Lavecchia G, Uslenghi C. Ex vivo evaluation of Pidotimod activity in patients with chronic obstructive. Arzneimittelforschung. 1994;44:1503\u20135.","journal-title":"Arzneimittelforschung"},{"key":"195_CR85","first-page":"434","volume":"25","author":"J Chen","year":"2006","unstructured":"Chen J, Wang H, Liu Y, Xia C, Qi M. Immunological function of T-lymphocyte in the elderly with chronic obstuctive pulmonary disease during acute exacerbations medication intervention. Chin J Geriatr. 2006;25:434\u201340.","journal-title":"Chin J Geriatr"},{"key":"195_CR86","first-page":"1495","volume":"44","author":"E Pozzi","year":"1994","unstructured":"Pozzi E, Dolcetti A, Orlandi O, Cirianni C, Moreo G, Piacenza G, et al. Pidotimod in the treatment in patients affected by bacterial exacerbations of chronic bronchitis. Arzneim Forsch Drug Res. 1994;44:1495\u20138.","journal-title":"Arzneim Forsch Drug Res"},{"key":"195_CR87","first-page":"253","volume":"3","author":"R Cogo","year":"1993","unstructured":"Cogo R, Ramponi A, Monzani G, Uslenghi C, Girardello R. Valutazione dell\u2019attivit\u00e0 del Pidotimod sulla secrezione di IgA in pazienti affetti da BPCO. Giorn It Allergol Immunol Clin. 1993;3:253\u20139.","journal-title":"Giorn It Allergol Immunol Clin"},{"key":"195_CR88","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/ACI.0000000000000416","volume":"18","author":"GW Canonica","year":"2018","unstructured":"Canonica GW, Ferrando M, Baiardini I, Puggioni F, Racca F, Passalacqua G, et al. Asthma: personalized and precision medicine. Curr Opin Allergy Clin Immunol. 2018;18:51\u20138.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"195_CR89","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/ni.3049","volume":"16","author":"BN Lambrecht","year":"2015","unstructured":"Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16:45\u201356.","journal-title":"Nat Immunol"},{"key":"195_CR90","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.anai.2015.12.024","volume":"116","author":"M Desai","year":"2016","unstructured":"Desai M, Oppenheimer J. Elucidating asthma phenotypes and endotypes: progress towards personalized medicine. Ann Allergy Asthma Immunol. 2016;116:394\u2013401.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"195_CR91","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343\u201373.","journal-title":"Eur Respir J"},{"key":"195_CR92","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.jaci.2017.03.031","volume":"140","author":"E Shemesh","year":"2017","unstructured":"Shemesh E, Kleinman LC. Asthma: the past, future, environment, and costs. J Allergy Clin Immunol. 2017;140:688\u20139.","journal-title":"J Allergy Clin Immunol"},{"issue":"56","key":"195_CR93","first-page":"323","volume":"1","author":"KM Phillips","year":"2018","unstructured":"Phillips KM, Bergmark RW, Hoehle LP, Caradonna DS, Gray ST, Sedaghat AR. Chronic rhinosinusitis exacerbations are differentially associated with lost productivity based on asthma status. Rhinology. 2018;1(56):323\u20139.","journal-title":"Rhinology"},{"key":"195_CR94","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/ACI.0000000000000492","volume":"19","author":"C Crimi","year":"2019","unstructured":"Crimi C, Ferri S, Crimi N. Bronchiectasis and asthma: a dangerous liaison? Curr Opin Allergy Clin Immunol. 2019;19:46\u201352.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"195_CR95","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1590\/S1807-59322009000800010","volume":"64","author":"C Bisaccioni","year":"2009","unstructured":"Bisaccioni C, Aun MV, Cajuela E, Kalil J, Agondi RC, Giavina-Bianchi P. Comorbidities in severe asthma: frequency of rhinitis, nasal polyposis, gastroesophageal reflux disease, vocal cord dysfunction and bronchiectasis. Clinics. 2009;64:769\u201373.","journal-title":"Clinics"},{"key":"195_CR96","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/resp.13026","volume":"22","author":"C Porsbjerg","year":"2017","unstructured":"Porsbjerg C, Menzies-Gow A. Co-morbidities in severe asthma: clinical impact and management. Respirology. 2017;22:651\u201361.","journal-title":"Respirology"},{"issue":"18","key":"195_CR97","first-page":"30673","volume":"S2213-2198","author":"E Heffler","year":"2018","unstructured":"Heffler E, Blasi F, Latorre M, Menzella F, Paggiaro P, Pelaia G, et al. The severe asthma network in Italy: findings and perspectives. J Allergy Clin Immunol Pract. 2018;S2213-2198(18):30673\u20131.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"195_CR98","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.alit.2018.11.006","volume":"68","author":"Melody G. Duvall","year":"2019","unstructured":"Duvall MG, Krishnamoorthy N, Levy BD. Non-type 2 inflammation in severe asthma is propelled by neutrophil cytoplasts and maintained by defective resolution. Allergol Int. 2018. \n                    https:\/\/doi.org\/10.1016\/j.alit.2018.11.006\n                    \n                  .","journal-title":"Allergology International"},{"key":"195_CR99","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12948-016-0049-9","volume":"14","author":"A Linneberg","year":"2016","unstructured":"Linneberg A, Dam Petersen K, Hahn-Pedersen J, Hammerby E, Serup-Hansen N, Boxall N. Burden of allergic respiratory disease: a systematic review. Clin Mol Allergy. 2016;14:12.","journal-title":"Clin Mol Allergy"},{"key":"195_CR100","doi-asserted-by":"publisher","first-page":"S773","DOI":"10.1016\/S0091-6749(97)70126-X","volume":"99","author":"SL Spector","year":"1997","unstructured":"Spector SL. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol. 1997;99:S773\u201380.","journal-title":"J Allergy Clin Immunol"},{"key":"195_CR101","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/1753465811431975","volume":"6","author":"T Ozdoganoglu","year":"2012","unstructured":"Ozdoganoglu T, Songu M. The burden of allergic rhinitis and asthma. Ther Adv Respir Dis. 2012;6:11\u201323.","journal-title":"Ther Adv Respir Dis"},{"key":"195_CR102","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1034\/j.1398-9995.2002.23664.x","volume":"57","author":"A Linneberg","year":"2002","unstructured":"Linneberg A, Henrik Nielsen N, Frolund L, Madsen F, Dirksen A, Jorgensen T, et al. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen allergy study. Allergy. 2002;57:1048\u201352.","journal-title":"Allergy"},{"key":"195_CR103","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.anai.2018.07.014","volume":"121","author":"NC Gunawardana","year":"2018","unstructured":"Gunawardana NC, Durham SR. New approaches to allergen immunotherapy. Ann Allergy Asthma Immunol. 2018;121:293\u2013305.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"195_CR104","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.imlet.2017.05.001","volume":"187","author":"S Qu","year":"2017","unstructured":"Qu S, Dai C, Qiu M, Zhang R, Wang C, Cui L, et al. Effects of pidotimod soluble powder and immune enhancement of Newcastle disease vaccine in chickens. Immunol Lett. 2017;187:14\u20138.","journal-title":"Immunol Lett"}],"container-title":["Multidisciplinary Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40248-019-0195-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40248-019-0195-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40248-019-0195-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T16:19:22Z","timestamp":1705681162000},"score":1,"resource":{"primary":{"URL":"https:\/\/mrmjournal.biomedcentral.com\/articles\/10.1186\/s40248-019-0195-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,4]]},"references-count":104,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["195"],"URL":"https:\/\/doi.org\/10.1186\/s40248-019-0195-2","relation":{},"ISSN":["2049-6958"],"issn-type":[{"value":"2049-6958","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,4]]},"assertion":[{"value":"24 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. GWC is member of the Editorial Board of Multidisciplinary Respiratory Medicine.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}